Banking

Quest Diagnostics Shows Rising Price Performance With Jump To 82 RS Rating

On Wednesday, Quest Diagnostics (DGX) hit a noteworthy technical benchmark, with its Relative Strength (RS) Rating rising into the 80-plus percentile with an upgrade to 82, an increase from 79 the day before.

When looking for the best stocks to buy and watch, one factor to watch closely is relative price strength.

This proprietary rating tracks market leadership by showing how a stock’s price action over the last 52 weeks measures up against that of other stocks on the major indexes.

Over 100 years of market history shows that the best stocks tend to have an RS Rating north of 80 in the early stages of their moves.


See How IBD Helps You Make More Money In Stocks


Quest Diagnostics stock is now considered extended and out of buy range after clearing a 136.69 buy point in a first-stage cup with handle. See if the stock forms a new pattern or follow-on buying opportunity like a three-weeks tight or pullback to the 50-day or 10-week moving average.

The company reported 124% EPS growth in its most recent report, while sales growth came in at 40%.

Quest Diagnostics stock earns the No. 2 rank among its peers in the Medical-Services industry group.  Joint (JYNT) is also among the group’s highest-rated stocks.

YOU MIGHT ALSO LIKE:

Join IBD Live And Learn Top Chart-Reading And Trading Techniques From The Pros
MarketSmith’s Tools Can Help The Individual Investor
Profit From Short-Term Trends With SwingTrader
Get Timely Buy & Sell Alerts With IBD Leaderboard
Find The Best Long-Term Investments With IBD Long-Term Leaders

 

Most Related Links :
Business News Governmental News Finance News

Need Your Help Today. Your $1 can change life.

[charitable_donation_form campaign_id=57167]

Source link

Back to top button